Structure-property Relationships Reported for the New Drugs Approved in 2023

Overview

Journal Mini Rev Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2024 Apr 27

PMID 38676492

Authors

Kihang Choi

Affiliations

Soon will be listed here.

Abstract

Drug-like properties play pivotal roles in drug adsorption, distribution, metabolism, excretion, and toxicity. Therefore, efficiently optimizing these properties is essential for the successful development of novel therapeutics. Understanding the structure-property relationships of clinically approved drugs can provide valuable insights for drug design and optimization strategies. Among the new drugs approved in 2023, which include 31 small-molecule drugs in the US, the structureproperty relationships of nine drugs were compiled from the medicinal chemistry literature, in which detailed information on pharmacokinetic and/or physicochemical properties was reported not only for the final drug but also for its key analogs generated during drug development. The structure- property relationships of nine newly approved drugs are summarized, including three kinase inhibitors and three G-protein-coupled receptor antagonists. Several optimization strategies, such as bioisosteric replacement and steric handle installation, have successfully produced clinical candidates with enhanced physicochemical and pharmacokinetic properties. The summarized structure- property relationships demonstrate how appropriate structural modifications can effectively improve overall drug-like properties. The ongoing exploration of structure-property relationships of clinically approved drugs is expected to offer valuable guidance for developing future drugs.

References

Leeson P, Springthorpe B . The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov. 2007; 6(11):881-90. DOI: 10.1038/nrd2445. View

Di L, Kerns E, Carter G . Drug-like property concepts in pharmaceutical design. Curr Pharm Des. 2009; 15(19):2184-94. DOI: 10.2174/138161209788682479. View

Leeson P, Young R . Molecular Property Design: Does Everyone Get It?. ACS Med Chem Lett. 2015; 6(7):722-5. PMC: 4499821. DOI: 10.1021/acsmedchemlett.5b00157. View

Waring M, Arrowsmith J, Leach A, Leeson P, Mandrell S, Owen R . An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015; 14(7):475-86. DOI: 10.1038/nrd4609. View

Donovan D, De Fusco C, Kuhnke L, Reichel A . Trends in Molecular Properties, Bioavailability, and Permeability across the Bayer Compound Collection. J Med Chem. 2023; 66(4):2347-2360. DOI: 10.1021/acs.jmedchem.2c01577. View

Choi K . Structure-property Relationships Reported for the New Drugs Approved in 2022. Mini Rev Med Chem. 2023; 24(3):330-340. DOI: 10.2174/1389557523666230519162803. View

Mullard A . 2022 FDA approvals. Nat Rev Drug Discov. 2023; 22(2):83-88. DOI: 10.1038/d41573-023-00001-3. View

Choi K . The Structure-property Relationships of Clinically Approved Protein Kinase Inhibitors. Curr Med Chem. 2022; 30(22):2518-2541. DOI: 10.2174/0929867329666220822123552. View

Janku F, Yap T, Meric-Bernstam F . Targeting the PI3K pathway in cancer: are we making headway?. Nat Rev Clin Oncol. 2018; 15(5):273-291. DOI: 10.1038/nrclinonc.2018.28. View

10.

Huang J, Chen L, Wu J, Ai D, Zhang J, Chen T . Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions. J Med Chem. 2022; 65(24):16033-16061. DOI: 10.1021/acs.jmedchem.2c01070. View

11.

McHardy T, Caldwell J, Cheung K, Hunter L, Taylor K, Rowlands M . Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt). J Med Chem. 2010; 53(5):2239-49. PMC: 2832868. DOI: 10.1021/jm901788j. View

12.

Addie M, Ballard P, Buttar D, Crafter C, Currie G, Davies B . Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J Med Chem. 2013; 56(5):2059-73. DOI: 10.1021/jm301762v. View

13.

Skorupskaite K, Anderson R . Hypothalamic neurokinin signalling and its application in reproductive medicine. Pharmacol Ther. 2021; 230:107960. DOI: 10.1016/j.pharmthera.2021.107960. View

14.

Depypere H, Lademacher C, Siddiqui E, Fraser G . Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs. 2021; 30(7):681-694. DOI: 10.1080/13543784.2021.1893305. View

15.

Hoveyda H, Fraser G, Roy M, Dutheuil G, Batt F, El Bousmaqui M . Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I). J Med Chem. 2015; 58(7):3060-82. DOI: 10.1021/jm5017413. View

16.

Hoveyda H, Fraser G, Dutheuil G, El Bousmaqui M, Korac J, Lenoir F . Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II). ACS Med Chem Lett. 2015; 6(7):736-40. PMC: 4499830. DOI: 10.1021/acsmedchemlett.5b00117. View

17.

Colden M, Kumar S, Munkhbileg B, Babushok D . Insights Into the Emergence of Paroxysmal Nocturnal Hemoglobinuria. Front Immunol. 2022; 12:830172. PMC: 8831232. DOI: 10.3389/fimmu.2021.830172. View

18.

Mastellos D, Ricklin D, Lambris J . Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019; 18(9):707-729. PMC: 7340853. DOI: 10.1038/s41573-019-0031-6. View

19.

Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams C . Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A. 2019; 116(16):7926-7931. PMC: 6475383. DOI: 10.1073/pnas.1820892116. View

20.

Mainolfi N, Ehara T, Karki R, Anderson K, Mac Sweeney A, Liao S . Discovery of 4-((2,4)-4-Ethoxy-1-((5-methoxy-7-methyl-1-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem. 2020; 63(11):5697-5722. DOI: 10.1021/acs.jmedchem.9b01870. View